What the FDA Galleri Review Means for Patients Considering a Multi-Cancer Blood Test

By Kim Lockheimer, PhD, DFM · September 2, 2026

On September 23, 2026, the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee meets to review GRAIL's premarket approval application for the Galleri multi-cancer early detection test. This is the first time an FDA advisory panel has convened to evaluate a premarket approval application for a test in this category. The outcome matters well beyond one product.

If you are considering this test, or if you have already taken it and are waiting on a result, the coverage over the next several weeks will be heavy on regulatory framing and light on the question you are actually asking. This is written to address that gap.

What the panel is reviewing

Galleri is a next-generation sequencing test that looks for cancer-associated methylation patterns in cell-free DNA isolated from peripheral whole blood. The proposed indication is screening in adults aged 50 and older, alongside guideline-recommended screening rather than in place of it. When the test detects a signal, it also predicts the likely tissue or organ of origin.

GRAIL submitted the application in January 2026. The test received Breakthrough Device designation in 2018. The submission draws on PATHFINDER 2, a US study of 25,490 participants, and the NHS-Galleri trial, which enrolled more than 70,000.

The panel provides independent recommendations to the FDA. Those recommendations are not binding, and a panel vote is not an approval. Any approval decision follows separately.

What a cancer signal detected result actually means

This is the point most coverage moves past too quickly. A cancer signal detected result is not a diagnosis. It indicates that the assay identified methylation patterns consistent with malignancy somewhere in the body. It does not identify a tumor, a stage, or a site with certainty. The predicted signal origin narrows the search. It does not end it.

A no cancer signal detected result is also not a clean bill of health. The test does not detect every cancer, and it does not detect every stage of the cancers it can find. A negative result does not change what your guideline-recommended screening should look like.

Both of these distinctions get lost in consumer messaging, and both of them change how a result should be handled.

What happens after a positive result

A cancer signal detected result begins a diagnostic workup. Depending on the predicted origin, that typically means imaging, sometimes endoscopy, sometimes tissue sampling, and often more than one round of each.

The interval between the result and an answer is the part nobody prepares people for. It can run weeks. During that window there is a result in hand, a probable location, and no confirmed diagnosis. Some workups end without finding anything at all, which is a legitimate outcome and not a failure of the workup.

If you are going to take this test, understand that a positive result commits you to that process. That is worth deciding in advance rather than in the moment.

Reading the coverage carefully

Some coverage of the upcoming review describes the clinical data as mixed. That framing deserves context rather than dismissal. The metric that matters most in screening a population without symptoms is not sensitivity. It is specificity and the resulting positive predictive value. A test applied to a large, mostly healthy population will generate false positives even at high specificity, and each false positive carries downstream cost, radiation exposure, procedural risk, and sustained anxiety. That tradeoff is the substance of what the panel will debate.

A useful way to read any figure you encounter over the next several weeks is to ask which population it came from, and whether it describes the chance of a cancer given a positive test or the chance of a positive test given a cancer. Those are different numbers and they are frequently conflated.

Where independent interpretation fits

MITOTICS® does not sell, order, or collect this test, and has no financial relationship with any laboratory. That independence is the point.

If you are holding a molecular result and trying to understand what it does and does not establish, that is the work this practice does. Records are reviewed, testing is interpreted against the current evidence, and findings are explained in language you can actually use in a conversation with your oncology team.

This is scientific advisory work. It is not medical care, it does not establish a physician-patient relationship, and it does not replace the judgment of your treating clinicians.